In several cancers, including HNSCC, the expression of glucose transporter 1 (GLUT1) is often elevated, and in conjunction with enhanced mTOR signalling (mTORC1 and C2), the pair activates key oncogenic drivers, including c-MYC and HIF-1α [44,45,46,47]. Here, MYC is linked to cancer.